At Rocky Mountain Hormone & Weight Loss Clinic, we are proud to announce that the U.S. Food and Drug Administration has approved semaglutide (Wegovy) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). The drug is a once weekly, under-the-skin injection (subcutaneous) that is indicated for chronic weight management in patients with a body mass index (BMI) of 27 or greater who have at least one weight-related ailment or in patients with a BMI of 30 or greater.

Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake, making it a powerful appetite suppressant. In addition, it increases the production of insulin and inhibits glucagon, which is a hormone that increases blood sugar. It has been known to aid not only in weight loss, but helps to lower glucose levels in those who are pre-diabetic or who have type 2 diabetes.

At Rocky Mountain Hormone & Weight Loss Clinic, we start at a low dose of semaglutide which can be gradually increased over 16 to 20 weeks. We also recommend pairing the semaglutide injection with either a vitamin b-12 injection or one of our lipotropic injections (lipo-lean, vita-chrom, or the mega-burn) for increased energy and metabolism.

We trust that you will have a successful and safe experience with the semaglutide injection. However, you are NOT a good candidate for semaglutide if you have any of the following: diabetic retinopathy, low blood sugar, decreased kidney function, pancreatitis, medullary thyroid cancer (or a family history of medullary thyroid carcinoma), or multiple endocrine neoplasia type 2. For your initial visit, please contact our office to schedule an appointment.